Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Very early PET1-adapted brentuximab vedotin-based therapy for advanced Hodgkin lymphoma
NL-OMON50149Phase 2Recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Dec 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of brentuximab vedotin in classical Hodgkin lymphoma (cHL) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Modified progression-free survival rate at 2 years. Started Dec 2019; status: recruiting.
02
Drugs
brentuximab vedotin
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NL-OMON50149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50149.